ULTRAGENYX PHARMACEUTICAL INC. Preferred Stock Dividends and Other Adjustments
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Preferred Stock Dividends and Other Adjustments of $4.81 million for the 12-month period ending 2014-12-31, per its 10-K filed 2017-02-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsAndOtherAdjustments · last filed 2017-02-17
- ULTRAGENYX PHARMACEUTICAL INC. preferred stock dividends and other adjustments for the quarter ending 2014-12-31 was $0.00, a 100.00% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. preferred stock dividends and other adjustments for the quarter ending 2014-09-30 was $0.00, a 100.00% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. preferred stock dividends and other adjustments for the quarter ending 2014-06-30 was $0.00, a 100.00% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. preferred stock dividends and other adjustments for the quarter ending 2014-03-31 was $4.81M, a 227.07% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. preferred stock dividends and other adjustments for fiscal 2014 was $4.81M, a 68.41% decline from fiscal 2013.
- ULTRAGENYX PHARMACEUTICAL INC. preferred stock dividends and other adjustments for fiscal 2013 was $15.22M, a 371.61% increase from fiscal 2012.
- ULTRAGENYX PHARMACEUTICAL INC. preferred stock dividends and other adjustments for fiscal 2012 was $3.23M.
| Period end | Preferred Stock Dividends and Other Adjustments 3 month | Preferred Stock Dividends and Other Adjustments 6 month | Preferred Stock Dividends and Other Adjustments 9 month | Preferred Stock Dividends and Other Adjustments 12 month |
|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $0.00 derived: sum of 2 quarters · filed 2017-02-17 | $0.00 derived: sum of 3 quarters · filed 2017-02-17 | $4.81M 10-K · filed 2017-02-17 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $0.00 derived: sum of 2 quarters · filed 2015-11-10 | $4.81M 10-Q · filed 2015-11-10 | $12.16M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $4.81M 10-Q · filed 2015-08-14 | $12.16M derived: sum of 3 quarters · filed 2016-02-26 | $16.32M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-03-31 | $4.81M 10-Q · filed 2015-05-12 | $12.16M derived: sum of 2 quarters · filed 2016-02-26 | $16.32M derived: sum of 3 quarters · filed 2016-02-26 | $18.56M derived: sum of 4 quarters · filed 2016-02-26 |
| 2013-12-31 | $7.35M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $11.51M derived: sum of 2 quarters · filed 2016-02-26 | $13.75M derived: sum of 3 quarters · filed 2016-02-26 | $15.22M 10-K · filed 2016-02-26 |
| 2013-09-30 | $4.16M 10-Q · filed 2014-11-10 | $6.40M derived: sum of 2 quarters · filed 2014-11-10 | $7.87M 10-Q · filed 2014-11-10 | |
| 2013-06-30 | $2.24M 10-Q · filed 2014-08-11 | $3.71M 10-Q · filed 2014-08-11 | ||
| 2013-03-31 | $1.47M 10-Q · filed 2014-05-12 | |||
| 2012-12-31 | $3.23M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |